Viatris Inc.

VTRS · NASDAQ · USD

Analysis

Last 4 earnings calls · through Q2 FY2026

Viatris is growing again after a stretch of declining sales, and the cost cuts are reaching profit faster than management planned. The medicines meant to keep that growth going are still in front of the FDA. How much of the planned savings has already reached profit?

  • Profit is growing much faster than sales, thanks to the cost cuts.

    Revenue rose about 3.5% in Q2 FY2026 while profit is guided to grow far faster, because the savings program is landing ahead of plan. Management calls it 'delivering the savings we committed to' — that money pays for the launches. Which parts of the business are being cut to get there?

  • One market is carrying the growth: China.

    Greater China grew 16% in Q2 FY2026 and now supplies about a fifth of revenue, while emerging markets shrank on supply problems and Japan keeps slipping on price cuts. Management expects a new hospital purchasing policy to slow China. How much of China's sales come from e-commerce versus hospitals?

  • A plant fire is costing sales while the big launches wait.

    Nashik is expected to cost $100 million to $150 million of second-half sales, while meloxicam's approval and the two big trial readouts, cenerimod and selatogrel, sit in late 2026 and 2027. Until then growth rests on savings and China.

Bullish
  • Greater China commercial execution
    The bull case rests on commercial execution in China, where investment in retail and e-commerce has turned mature established brands into a reliable growth source.
  • Cost savings program
    Management has finished a company-wide cost review and put a number on it, and the savings are expected to fund both margin expansion and reinvestment in new products.
  • New product launches
    Several near-term approvals, led by a fast-acting pain medicine and a weekly contraceptive patch, are expected to add higher-margin branded revenue on top of the base business.
Bearish
  • Generic price pressure
    The bear case is that most of the portfolio is off-patent and sold where governments set prices, so new revenue is offset by steady erosion in existing products.
  • Manufacturing disruptions
    Repeated plant problems, from an import alert in Indore to a fire in Nashik, keep removing revenue that management has to guide around rather than replace.
  • Dependence on a few products
    A small group of products supplies a large share of sales, so a single patent loss or new competitor in a big market can outweigh growth across the rest of the portfolio.
See the full bull & bear case
PoliticiansInstitutionsInsiders
PoliticianTransactionAmountTradedFiled
Ro Khanna
Democratic · House · CA-17
Sale≥$1KMay 27Jun 9
Gilbert Ray Cisneros, Jr.
Democratic · House · CA-31
Purchase≥$1KNov 18Dec 15
Ro Khanna
Democratic · House · CA-17
Purchase≥$1KApr 23May 12
Robert Bresnahan
Republican · House · PA-8
Sale≥$1KApr 8May 8
Gilbert Ray Cisneros, Jr.
Democratic · House · CA-31
Sale≥$1KMar 31Apr 7

Congressional trading data provided by QuiverQuant

See all
Product segmentsGeography
FY2025 · USD

How Viatris turned $14.3B of revenue into $5.0B of gross profit.

Revenue
Brands$9.2B▼ 0.18% YoY
Generics$5.1B▼ 7.76% YoY
Total revenue$14.3B
Gross profit$5.0B35.1%
See all